Interleukin 6 inhibition: RA and beyond

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 225-229

  Woodrick, Robert S ^a   Ruderman, Eric M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; TOCILIZUMAB;

ADULT ONSET STILL DISEASE; ANAPHYLAXIS; ARTICLE; BACTERIAL ARTHRITIS; COLON ULCER; DEHYDRATION; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; HUMAN; HYPERLIPIDEMIA; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; NEUTROPENIA; PNEUMONIA; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

EID: 80054116962     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kremer JM, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609-21.
2. Nishimoto N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-7.
3. Hashimoto J, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011;21(1):10-5.
4. Kawashiri SY, Kawakami A, Iwamoto N, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011. [Epub ahead of print]
5. Burmester GR, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755-759.
6. Weinblatt M, et al. Safety of Tocilizumab monotherapy and TCZ plus DMARDs in a US RA population with inadequate response to biologics or DMARDs: The ACT-STAR study. London: EULAR, 2011.
7. Campbell L, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552-62.
8. Singh JA, et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.
9. van Vollenhoven RF, et al. Gastrointestinal Safety in Patients with Rheumatoid Arthritis Treated with Tocilizumab: Data From Roche Clinical Trials. Arthritis Rheum. 2009;60(Suppl 10):1613.
10. Curtis JR, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum. 2011;63(2):346-51.
11. Honda H, Kida H, Yoshida M, et al. Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab. Mod Rheumatol. 2011. [Epub ahead of print]
12. Roux C, Breuil V, Albert C, et al. Ophthalmic herpes zoster infection in patients with rheumatoid arthritis who were treated with tocilizumab. J Rheumatol. 2011;38(2):399.
13. van Duin D, Miranda C. Husni E., Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy. Emerg Infect Dis. 2011;17(4):754-6.
14. de Benedetti F, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34(9):1158-63.
15. Lepore L, et al. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol. 1994;12(5):561-5.
16. Rooney M, et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol. 1995;34(5):454-60.
17. Yokota S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998-1006.
18. de Benedetti F, Brunner H, Ruperto N. Efficacy and safety of tocilizumab in patients wtih systemic juvenile idiopathic arthritis (SJIA): 12-week data from the phase 3 TENDER trial. Ann Rheum Dis. 2010;69(Suppl 3):146.
19. de Benedetti F, et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): TENDER 52-week data. London: EULAR, 2011, p. OP0006.
20. Chen DY, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004;31(11):2189-98.
21. De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis. 2009;68(1):153-4.
22. Iwamoto M, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002;46(12):3388-9.
23. Matsumoto K, et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28(4):485-7.
24. Nakahara H, et al. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19(1):69-72.
25. Sumida K, et al. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010;29(10):1191-4.
26. Yoshimura M, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol. 2010;28(1):141-2.
27. Puechal X, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken). 2011;63(1):155-9.
28. Illei GG, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-52.
29. Brulhart L, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010;77(6):625-6.
30. Henes JC, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010;69(12):2217-8.
31. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol. 2011. [Epub ahead of print]
32. Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine. 2010;77(6):624-5.
33. Narazaki M, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50(7):1344-6.
34. Hirano T, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2011. [Epub ahead of print]
35. Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.